effects of Silymarin in the Prevention of hyperbilirubinemia

Phase 3

Recruiting

• Conditions: eonatal jaundice, unspecified.; Neonatal jaundice, unspecified; P59.9

• Registration Number: IRCT20231120060123N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Full-term newborns who are negative for the Coombs test at birth.
Healthy full-term newborns who do not require phototherapy.
Newborns whose bilirubin levels are not in the range requiring blood exchange.
Newborns with no history of the mother taking any kind of medication during pregnancy.

Exclusion Criteria

Newborns with RH incompatibility who are positive for the Coombs test.
Newborns with an increase in bilirubin to the level requiring blood exchange.
Newborns requiring phototherapy on the first day of birth.
Deterioration in the newborn's condition during hospitalizationwith dehydration, sepsis, pneumonia, anemia, severe weight loss, hypoglycemia, renal failure, or heart failure.
Newborns with a history of the mother taking any kind of medication during pregnancy or mothers who have received phenobarbital.
Newborns who experience severe drug reactions following the use of silymarin.
Parents' refusal to continue treatment.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Transcutaneous bilirubin level. Timepoint: 24,48 and 72 hours after birth. Method of measurement: Bilichek device.